All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-03-25T12:20:40.000Z

How good are we in generating CAR T-cells in a virus-free environment?

By Alice Hyde
Featured
Michael Hudecek
Mar 25, 2021
Share:

Bookmark this article

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Michael Hudecek, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How good are we in generating CAR T-cells in a virus-free environment?

How good are we in generating CAR T-cells in a virus-free environment?

Michael Hudecek discusses the impact of the Sleeping Beauty transposon, as well as talking about the results from the CARAMBA-1 trial which uses SLAMF7 CAR T-cells.

More about...
CAR therapyCAR-T 2021

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Answering the common challenges facing real-world CAR T-cell therapies

During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session on the ins and outs of CAR T-cells in the real world. Here, Michael Hudecek,...

Jul 21, 2023
Add bookmark

Answering the common challenges facing real-world CAR T-cell therapies

During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session on the ins and outs of CAR...

Jul 21, 2023
Add bookmark

What are the critical issues to address for outpatient administration of CAR T-cell therapy?

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What are the critical...

Feb 16, 2021
Add bookmark

What are the critical issues to address for outpatient administration of CAR T-cell therapy?

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Ulrich Jäger, Medical University of...

Feb 16, 2021

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox